News Releases

Date Title and Summary Additional Formats
Toggle Summary HTG EdgeSeq Mouse mRNA Tumor Response Panel Used by Researchers Targeting Cardiac Fibrosis with Engineered T-cells
TUCSON, Ariz. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the HTG EdgeSeq Mouse mRNA Tumor Response Panel as a way to identify endogenous targets of cardiac
View HTML
Toggle Summary HTG EdgeSeq miRNA Whole Transcriptome Assay is Highly Reproducible in Biofluids for Potential Use as a Biomarker
TUCSON, Ariz. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the reproducibility of the HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA), as reported in a
View HTML
Toggle Summary HTG Molecular Diagnostics Receives European Patent Grant Notification for Methods for Subtyping Diffuse Large B-cell Lymphoma
TUCSON, Ariz. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has received notification of validation of European patent number EP 3356554 for its methods for
View HTML
Toggle Summary HTG Molecular Diagnostics Announces Preliminary 2019 Unaudited Financial Results
Preliminary full year 2019 unaudited revenue of $19.2 million Cash and cash equivalents of $33.0 million as of December 31, 2019 TUCSON, Ariz. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision
View HTML
Toggle Summary HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on the Future of Precision Medicine
TUCSON, Ariz. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Friday, December 13 th in Boston,
View HTML
Toggle Summary HTG Molecular Diagnostics Expands Analytics Capabilities with Release of New Software Update
HTG EdgeSeq Reveal software version 2.0.0 streamlines data analysis process and enhances user experience TUCSON, Ariz. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, yesterday
View HTML
Toggle Summary HTG Molecular Diagnostics Reports Third Quarter 2019 Results
 Product and product-related services revenue increased by 228% and 125% in the three and nine-month periods, respectively, compared to the prior year periods Call scheduled for today, November 12 , at 4:30pm ET TUCSON, Ariz. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
View HTML
Toggle Summary HTG Molecular Diagnostics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 12
TUCSON, Ariz. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the third quarter ended September 30, 2019 after the market close on
View HTML
Toggle Summary HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on Breast Cancer Molecular Diagnostics on October 29
TUCSON, Ariz. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) , a diagnostic company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Tuesday, October 29 th in New York City .
View HTML
Toggle Summary HTG Announces the Launch of its New Autoimmune Profiling Assay
TUCSON, Ariz. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced it will begin taking orders for its new 2,002-gene HTG EdgeSeq Autoimmune Panel, which is expected to be
View HTML